May 29, 2018 – As the dust settles on the Trump administration’s drug pricing blueprint, the pharmaceutical industry is facing a mixed bag of potential short- and long-term impacts, according to Kate Rawson, Senior Editor, Prevision Policy and The RPM Report. Rawson, who spoke May 23 at the Coalition for Healthcare Communication Rising Leaders Conference […]
Read more
By John Kamp, Coalition for Healthcare Communication Executive Director May 16, 2018 — Pharma fared quite well Friday at a White House press briefing outlining ways to reduce drug prices. Indeed, Wall Street responded by increasing the share prices of major drug companies, and even the share prices of payers and insurers, longtime marketing “frenemies.” […]
Read more